# 1 Role of sociodemographic, clinical, behavioral, and molecular factors in precision

# 2 prevention of type 2 diabetes: a systematic review

- 3 Dhanasekaran Bodhini,<sup>1</sup> Robert W. Morton,<sup>2,3</sup> Vanessa Santhakumar,<sup>4</sup> Mariam Nakabuye,<sup>5</sup>
- 4 Hugo Pomares-Millan,<sup>6,7</sup> Christoffer Clemmensen,<sup>5</sup> Stephanie L. Fitzpatrick,<sup>8</sup> Marta Guasch-
- 5 Ferre,<sup>5,9</sup> James S. Pankow,<sup>10</sup> Mathias Ried-Larsen,<sup>11,12</sup> Paul W. Franks,<sup>3,9,13,14</sup> ADA/EASD
- 6 Precision Medicine in Diabetes Initiative, Deirdre K. Tobias,<sup>4,9\*</sup> Jordi Merino,<sup>5,15\*</sup>
- 7 Viswanathan Mohan,<sup>1,16</sup>\* Ruth J.F. Loos<sup>5,16</sup>\*
- 8
- 9 \*These authors contributed equally
- 10

# 11 Affiliations:

- <sup>1</sup> Madras Diabetes Research Foundation, Chennai, India.
- <sup>2</sup> Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Canada
- 14 and Population Health Research Institute, Hamilton, Canada.
- <sup>3</sup> Department of Translation Medicine, Novo Nordisk Foundation, Hellerup, Denmark
- <sup>4</sup> Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital
- 17 and Harvard Medical School, Boston, MA, USA.
- <sup>5</sup> Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and
- 19 Medical Sciences, University of Copenhagen, Denmark.
- <sup>6</sup> Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund
   University, Skåne University Hospital Malmö, Malmö, Sweden.
- <sup>7</sup> Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
- <sup>8</sup> Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell
- 24 Health, Manhasset, NY, USA.
- <sup>9</sup> Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, US.
- <sup>10</sup> Division of Epidemiology and Community Health, School of Public Health, University of
- 27 Minnesota.
- <sup>11</sup> Centre for Physical Activity Research, Rigshospitalet.
- <sup>12</sup> Institute for Sports and Clinical Biomechanics, University of Southern Denmark.
- <sup>13</sup> Lund University Diabetes Centre, Department of Clinical Sciences, Lund University,
   Malmo, Sweden.
- <sup>14</sup> Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of
- 33 Medicine, University of Oxford, Oxford, UK.
- <sup>15</sup> Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston,
- 35 MA, USA.
- <sup>16</sup> Dr. Mohan's Diabetes Specialities Centre, Chennai, India.

- <sup>17</sup> Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount
- 38 Sinai, New York, NY

39

## 40 **Correspondence**:

- 41 Ruth J.F. Loos
- 42 University of Copenhagen
- 43 Faculty of Health and Medical Sciences
- 44 Novo Nordisk Foundation Center for Basic Metabolic Research
- 45 Blegdamsvej 3b
- 46 N-2200 Copenhagen
- 47 Denmark
- 48 Email: ruth.loos@sund.ku.dk
- 49 ORCID ID: 0000-0002-8532-5087
- 50

## 51 Acknowledgment

- 52 We thank Hugo Fitipaldi, Esther González-Padilla, Alisha Sha, and Jiaxi Yang for attending
- 53 some of the working group meetings and/or for reviewing some of the abstracts.
- 54

55 The Precision Medicine in Diabetes Initiative (PMDI) was established in 2018 by the 56 American Diabetes Association (ADA) in partnership with the European Association for the 57 Study of Diabetes (EASD). The ADA/EASD PMDI includes global thought leaders in 58 precision diabetes medicine who are working to address the burgeoning need for better 59 diabetes prevention and care through precision medicine [Nolan et al, Diabetes Care, 2022]. 60 This Systematic Review is written on behalf of the ADA/EASD PMDI as part of a comprehensive evidence evaluation in support of the 2<sup>nd</sup> International Consensus Report on 61 62 Precision Diabetes Medicine [Tobias et al, Nat Med year?].

### 63 Abstract

64 The variability in the effectiveness of type 2 diabetes (T2D) preventive interventions 65 highlights the potential to identify the factors that determine treatment responses and those 66 that would benefit the most from a given intervention. We conducted a systematic review to 67 synthesize the evidence to support whether sociodemographic, clinical, behavioral, and 68 molecular characteristics modify the efficacy of dietary or lifestyle interventions to prevent 69 T2D. Among the 80 publications that met our criteria for inclusion, the evidence was low to 70 very low to attribute variability in intervention effectiveness to individual characteristics such 71 as age, sex, BMI, race/ethnicity, socioeconomic status, baseline behavioral factors, or 72 genetic predisposition. We found evidence, albeit low certainty, to support conclusions that 73 those with poorer health status, particularly those with prediabetes at baseline, tend to 74 benefit more from T2D prevention strategies compared to healthier counterparts. Our 75 synthesis highlights the need for purposefully designed clinical trials to inform whether 76 individual factors influence the success of T2D prevention strategies.

77

## 78 INTRODUCTION

79 Diabetes affects over 530 million people worldwide.<sup>1</sup> Around 90% of all diabetes is estimated 80 to be type 2 diabetes (T2D), a non-autoimmune condition with marked pathophysiological heterogeneity.<sup>2</sup> In many cases, weight loss interventions have demonstrated to delay 81 82 progression.<sup>3-6</sup> yet T2D remains a major cause of morbidity and mortality globally.<sup>7</sup> Chronic 83 inadequate control of hyperglycemia causes downstream microvascular and macrovascular complications that drive the costly and debilitating T2D public health burden.<sup>7</sup> Coupled with 84 85 its increasing incidence, public health, and clinical efforts need to optimize effective 86 upstream strategies for T2D prevention.

Landmark randomized intervention trials have demonstrated the effectiveness of intensive lifestyle interventions and glucose-lowering drug therapies for delaying the onset of T2D in patients at high risk.<sup>3–6</sup> However, T2D incidence has only escalated in the decades since, despite the success of early clinical trials. It is unclear what underscores the underwhelming scalability and translation of effective prevention strategies in real-world settings, and precision prevention research may contribute to understanding this gap.

93 Precision prevention of T2D serves to minimize an individual's T2D risk factor profile and maximize the effectiveness of new or established strategies for disease prevention.<sup>8</sup> through 94 95 targeting of biological interactions and/or removal of barriers to access and adherence to 96 lifestyle modifications. For example, precision prevention approaches might use clinical (e.g., 97 age, sex, body mass index [BMI]), social (e.g., education attainment, socioeconomic status), 98 or molecular (e.g., genetic, 'omic traits) characteristics to inform strategies likely to elicit the 99 most effective or sustainable response for an individual, resulting in tailored prevention strategies.<sup>8–10</sup> 100

101 The purpose of this systematic review is to critically appraise the accumulated experimental 102 evidence underpinning the feasibility and effectiveness of the clinical translation of precision 103 prevention of T2D. The scope of our investigation included studies reporting the effect 104 modification of lifestyle, dietary, and other behavioral interventions for T2D prevention by any

- 105 of the following individual-level factors, including sociodemographics, clinical risk factors,
- 106 behavior, or molecular traits. This work was undertaken as part of a series of systematic
- 107 reviews conducted by the ADA/EASD Precision Medicine in Diabetes Initiative, an
- 108 international collaboration of global leaders in precision diabetes medicine.<sup>11</sup>

109

#### 110 METHODS

- 111 The systematic review protocol was pre-registered on the International Prospective Register
- 112 of Systematic Reviews (PROSPERO; CRD42021267686)

#### 113 Data sources and search

114 Our search included MEDLINE, Embase, and Cochrane Central Register of Controlled Trials 115 databases for studies reporting on the efficacy of lifestyle or behavioral interventions with 116 T2D incidence, published from 1/1/2000 to 7/15/2021. An experienced librarian developed a 117 search strategy (Supplement Table 1), which included combinations of keywords related to 118 behavioral intervention for preventing T2D (diet, lifestyle, physical activity, body weight), 119 study design, and health outcome, and was limited to the English language. We also 120 scanned the references of included manuscripts and the reference list of systematic reviews 121 published within the past two years to identify additional relevant studies.

#### 122 Study Selection

123 We included studies reporting the effect of a lifestyle, diet, or other behavioral interventions 124 vs. other active comparators or control on the incidence of T2D and reporting the results 125 stratified by any eligible factor. Eligible interventions of interest included lifestyle or 126 behavioral interventions, ranging from education on a single factor to intensive multi-127 component modification programs, weight loss, diet or supplementation, and physical 128 activity. Eligible stratification factors, or effect modifiers, included individual-level 129 sociodemographic (i.e., race/ethnicity, socioeconomic status/ education, location, age, sex), 130 clinical factors (i.e., BMI, dysglycemia, presence of comorbidities), behavioral (i.e., baseline 131 diet, physical activity) or molecular traits (i.e., genetics, metabolites). We did not review 132 population-level exposures such as built environment, pollution, or climate. Off-label 133 pharmaceutical interventions and bariatric surgery were beyond the scope of the review. We 134 included non-randomized and randomized clinical studies delivering an eligible intervention, 135 comparing against another active intervention, usual care, placebo control or non-control 136 group. We limited inclusion to studies in adults aged >18 years and enrolling at least 100.

137 Studies exclusively among individuals with a current or history of gestational diabetes were

138 excluded because they overlapped in scope with another PMDI consortium review.

#### 139 Screening, data extraction, and quality assessment

We used the Covidence online systematic review platform<sup>12</sup> for literature screening, data 140 141 extraction, and consensus. Screening consisted of two stages: [1] title and abstract and [2] 142 full text. At each screening stage, two independent reviewers determined the eligibility of the 143 citation, and in the case of disagreement, a third reviewer resolved the discrepancy. Among 144 the full papers accepted for inclusion in the review, two independent reviewers extracted 145 detailed information on the study design, participant characteristics, interventions and 146 comparators, effect modifiers, follow-up for T2D, and analytic approach. We extracted 147 findings related to effect modification of treatment vs. comparator on T2D risk, including 148 strata-specific treatment groups' T2D cases and incidence rates, or strata-specific treatment-149 comparator incidence rate ratios, relative risks, risk differences, etc., including measures of 150 variance. We also recorded results for tests for heterogeneity or interaction of the effect 151 modifier with the intervention effect on T2D and noted any text referring to tests performed 152 with "data not shown". We developed and piloted the data extraction template (Supplement 153 **Table 2**) and discrepancies were ruled on by a third reviewer.

154 We evaluated the studies' risk of bias using a modified JBI Critical Appraisal Checklist for randomized controlled trials.<sup>13</sup> performed by two independent reviewers and disagreements 155 156 resolved by a third reviewer. We modified the 13-item checklist to 9 questions tailored to 157 evaluating the quality of the study design, but with consideration for our primary interest in 158 stratified results rather than the total intervention effect for T2D risk. These 9 questions were 159 mainly based on randomization, interventions, treatment, and assessor blindness to 160 outcome assessment and our evaluation of these corresponded to color coding in a heat 161 map organized by intervention type and effect modifier (**Supplement Figure 1**).

#### 162 Synthesis of results

163 We collated the literature according to intervention type (e.g., lifestyle programs, dietary 164 supplements) and effect modifier analyzed (e.g., sex, age strata) for the synthesis of results. 165 We determined that a meta-analysis was not feasible among the studies included in our 166 review due to paucity and marked differences in the nature of the study populations, 167 interventions and comparators, and study designs, and effect modifiers analyzed. We 168 qualitatively evaluated the direction and magnitude of results and statistical tests among 169 each prevention strategy for each effect modifier. We weighed these qualitative and 170 quantitative results against their risk of bias and derived the certainty of the collective 171 evidence for an effect modifier's influence on an intervention strategy, guided by the Diabetes Canada cCinical Practice Scale.<sup>14</sup> Two reviewers, independently, assessed the 172 173 certainty of the evidence and resolved disagreements through consensus discussion.

174

175

### 176 **RESULTS**

The results of our systematic literature search are presented in the **Figure 1** attrition diagram. Of the 10,880 citations identified through database searches and other sources, 1,047 abstracts were retrieved for full-text review. From these, 80 publications met our inclusion criteria and data were extracted.

#### 181 Study characteristics

The 80 publications included in our review represented 33 unique intervention studies (Table 182 183 1, Supplement Table 3). Twenty-eight studies were randomized clinical trials (RCTs), three 184 studies were nonrandomized parallel group trials, and two studies were single-arm clinical 185 interventions. Fourteen intervention studies took place in Asia, 11 in Europe, seven in North 186 America, and one was a multicenter study that took place in Asia and Europe. Intervention 187 enrollment sample sizes ranged from 302 to 48,835 participants (Table 1). Twenty-two 188 studies included individuals at high risk for T2D, two studies at increased cardiovascular risk, 189 and other studies included the general population or other specific groups. The active 190 intervention times ranged from one single lifestyle counseling visit to active interventions 191 lasting up to 10 years (Supplement Figure 2).

192 Twenty-four of the included studies assessed the effect of a multi-component lifestyle 193 intervention program, focused on changes in diet, physical activity, smoking, or body weight 194 loss. Four studies implemented a dietary intervention, and five administered supplements. 195 Across multi-component lifestyle intervention studies, the comparator consisted of a less 196 intensive lifestyle program consisting of usual care or general lifestyle advice administered at 197 baseline. Active comparator groups for dietary intervention studies that focused on high-fat 198 diets consisted of a low-fat intervention. The active comparator for supplement studies 199 consisted of a placebo intervention. T2D was diagnosed in-person with an oral glucose 200 tolerance test (OGTT) in 27 studies, whereas in 6 studies, T2D was ascertained via self-201 report or through linkage with a healthcare registry database. The primary endpoint was T2D

incidence in 21 studies or a composite cardiovascular event in six studies (Table 1,
Supplement Table 3).

All except seven studies consisting of a multi-component lifestyle intervention program showed evidence that a lifestyle intervention reduces the risk of T2D, with estimated relative risk reduction ranging from 60% to 23% (**Supplement Table 3**). Available evidence also suggests that a high-fat diet, compared to a low-fat diet, reduces the relative risk of T2D. Evidence from studies using supplements showed a null effect on T2D risk reduction.

209 Our risk of bias assessment determined that the primary study design and approach was 210 generally low, particularly for the RCTs, owing to randomization methods and uniform 211 outcome assessment (**Supplement Figure 1**).However, common concerns for bias were 212 due to non-blinding of participants, deliverers, and outcomes assessors to treatment 213 assignment. Nonrandomized interventions and RCTs having additional concerns for study 214 design did have ratings of high risk of bias.

### 215 Sociodemographic and clinical factors

216 Some clinical trials, such as the Diabetes Prevention Program (DPP), the Finnish Diabetes 217 Prevention Study (DPS), or the PREDIMED study, were highly represented, with 20, 16, and 218 6 different publications from each study, respectively. Evidence presented in studies 219 investigating the effect of a lifestyle intervention according to differences in 220 sociodemographic and clinical characteristics did not indicate statistically different effects for 221 age, sex, race/ethnicity, or socioeconomic status. Evidence from studies investigating 222 sociodemographic interaction effects in dietary modification or supplementation trials 223 showed no significant heterogeneity in response to intervention according to these 224 characteristics (Table 2, Figure 2).

Fourteen studies investigated whether BMI modified the efficacy of multi-component lifestyle interventions. Nine of these studies showed that BMI is not associated with different responses to a lifestyle program, but five studies showed suggestive evidence that

228 individuals with low BMI could benefit most from a lifestyle intervention. Among these five 229 studies presenting evidence of the differential effect of a lifestyle intervention according to 230 BMI, four were conducted in Asia (**Table 3**). No appreciable evidence for interactions with 231 BMI was observed in studies that implemented a dietary or supplement intervention (Table 232 3). Eighteen studies tested the efficacy of an intensive lifestyle intervention for preventing 233 T2D stratified based on baseline glucose levels, impaired glucose tolerance, or prediabetes 234 status. Evidence presented in eight of these studies indicated statistically different effects 235 based on baseline dysglycemia, but other studies did not find evidence of effect 236 modifications. Three studies investigated family history of T2D as a potential lifestyle 237 intervention effect modifier, and only one provided suggestive evidence of heterogenous 238 treatment responses. Studies stratified by baseline cardiometabolic risk factors reported that 239 individuals with poorer health status, particularly those with dyslipidemia and metabolic 240 syndrome, tend to benefit more from dietary or supplement interventions than individuals 241 who are healthier (Table 3).

### 242 Behavioral factors

243 Several secondary studies have assessed whether baseline lifestyle factors (i.e., overall 244 dietary quality, alcohol intake, physical activity, and/or smoking) influence the efficacy of T2D 245 prevention interventions. Evidence presented in studies investigating the effect of a lifestyle 246 intervention according to baseline smoking status and physical activity indicates statistically 247 different effects, suggesting that smokers and those with lower levels of physical activity 248 benefited less from a lifestyle program (Table 4). Available studies reported no interactions 249 of baseline smoking status and physical activity levels with dietary or supplement 250 interventions on the risk of T2D. Among the four studies that focused on alcohol intake, only 251 one found that the lifestyle intervention was more effective in individuals who drink alcohol 252 frequently than in those who rarely drink. Six studies tested whether baseline diet modified 253 the association between supplements and the risk of T2D and found no evidence of 254 significant interactions (Table 4).

### 255 Molecular factors

256 The extent to which genetic predisposition modifies the efficacy of interventions to prevent 257 T2D was reported in 21 publications, and most of them were based on data from the DPP 258 and the DPS. Genetic predisposition was defined based on single genetic variants in 16 259 studies or genetic risk scores in five studies. While many of the T2D-associated loci 260 identified in the earlier GWAS studies have been examined for their potential roles as effect 261 modifiers, some reported evidence that individuals with specific genotypes could benefit the 262 most from a lifestyle intervention, but these studies rarely corrected for the number of 263 performed tests. Of the five studies that reported on the role of polygenic scores for T2D, 264 only one study showed that lifestyle intervention was more effective among individuals with a 265 high genetic risk.

266 Besides genetics, other molecular markers have also been studied for their potential effect 267 modification of prevention interventions. A posthoc analysis in the PREDIMED trial showed 268 that higher levels of plasma branched-chain amino acid levels at baseline attenuated the 269 beneficial effect of a Mediterranean diet for the prevention of T2D, but these findings have 270 been not replicated in independent studies. A separate study has found that individuals with 271 low plasma levels of miR-29a, miR-28-3p, miR-126 and high plasma levels of miR-150 have 272 a higher risk of developing T2D if they are allocated to a MedDiet, but not if they consume a 273 low-fat and high-carbohydrate diet. (Table 5, Figure 2).

## 274 Grading of evidence certainty

Although our systematic review included intervention studies, most of which were RCTs with low risk of bias, we evaluated certainty through our hypothesis of identifying valid effect modifiers to inform precision prevention. None of the studies included *a priori* consideration of intervention interactions with individual-level characteristics or risk factors in their study design, which were largely conducted as posthoc analyses. As a result, statistical power was often limited. Further, most did not adjust for individual-level risk factors, undermining validity

281 of interpreting the role of effect modifiers independent of other traits. These considerations

were factored into the major downgrading of the evidence (**Tables 2-5**)

283

#### 284 **DISCUSSION**

285 We performed a comprehensive systematic review to identify individual-level 286 sociodemographic, clinical, behavioral, or molecular factors that could modify the efficacy of 287 T2D prevention strategies. Overall, we find low to very low certainty of evidence that traits 288 such as age, sex, BMI, race/ethnicity, socioeconomic status, baseline lifestyle factors, or 289 genetics consistently and validly modify the effectiveness of lifestyle and behavioral 290 interventions. Low-certainty evidence was observed for health status at baseline; individuals 291 with poorer health, particularly those with prediabetes, were likely to benefit from prevention 292 strategies compared to individuals in better health. However, whether the modest benefit 293 reported in these studies was due to poor health status or other correlated risk factors 294 cannot be ascertained based on the available evidence.

295

296 Large randomized clinical trials have consistently demonstrated that a healthy lifestyle or dietary interventions can prevent or delay T2D.<sup>3,4,6,15</sup> However, there is large inter-individual 297 298 variability in response to these preventive interventions, in which some people seem to 299 greatly benefit from T2D preventive interventions. Precision prevention aims to identify 300 participant characteristics that determine this variability in response to ultimately tailor 301 preventive strategies to subgroups of individuals that are likely to benefit the most. So far, no 302 studies exist that were prospectively designed to determine interactions by a baseline trait or 303 factor with an intervention in prevention of T2D. We evaluated the evidence base and 304 identified several stratified posthoc analyses of existing prevention intervention trials. In 305 posthoc analyses, the participant population is stratified by a potential effect modifier, and 306 the efficacy of the intervention is tested within each stratum and compared across the strata, 307 which reduces statistical power and increases type 2 error. Furthermore, precision

308 prevention strategies may be optimized by incorporating several individual-level factors into 309 decision making, whereas the current literature is predominantly evaluating one stratified 310 trait as a time. For example, correlated behaviors such as physical activity, diet, and 311 smoking, might provide more information when considered collectively than on their own. 312 Clinical trials specifically designed to investigate the influence of sociodemographic, clinical, 313 behavioral, or molecular factors on the response to T2D preventive strategies are needed to 314 generate valid and robust evidence before the implementation of T2D precision prevention 315 strategies.

316

317 One area of promise warranting further research is the presence of prediabetes at baseline 318 and whether this may be targeted in future precision prevention research. Low certainty 319 evidence suggests that individuals at risk of T2D or with prediabetes at baseline benefit 320 slightly more of prevention interventions than individuals who are not at risk of T2D.<sup>3-6</sup> 321 However, the evidence is inconsistent, even though the studies report that a lifestyle 322 intervention, compared to standard care, results in higher T2D reduction rates among studies conducted in Asia.<sup>15-18</sup> Beyond the methodological limitations of the available 323 324 evidence, an additional reason for inconsistent evidence supporting the greater effectiveness 325 of lifestyle interventions for the prevention of T2D among individuals with prediabetes is due 326 to the heterogeneity that characterizes this condition. Prediabetes refers to a 327 pathophysiological state of early alterations in glucose metabolism that precedes the 328 development of diabetes, but the mechanism by which glucose is elevated are very different 329 and could range from those with primary alterations in insulin secretion pathways to those 330 with primary insulin resistance.<sup>19</sup> Clinical trials specifically designed to capture the nuances 331 and complexity of early glycemic alterations and whether individuals with distinct 332 pathophysiological features benefit from more targeted preventive interventions are needed 333 to fill the gap in current T2D precision prevention evidence.

334

335 Even though there are far more lifestyle intervention trials for the prevention of T2D than diet 336 alone and diet supplementation trials, collectively, however, results for effect modification by 337 any one factor are sparsely reported or arising from an evidence base of very different trials 338 and patient populations. Further, many of the secondary analyses included in this systematic 339 review are derived from two single clinical interventions. Findings from available evidence 340 contrast with recent clinical studies documenting variable responses to identical foods, diets, 341 or lifestyle interventions based on inter-individual differences in demographic, clinical, 342 genetic, gut microbiota, and lifestyle characteristics.<sup>20-22</sup> While these studies offer insights 343 into variable postprandial metabolic response, their short follow-up periods, the lack of time-344 series data and changes in parameters that could influence response to interventions, and 345 the inclusion of relatively young and healthy individuals preclude the generalizability to T2D 346 prevention efforts. Whether the promise of T2D precision prevention is matched by evidence 347 of the long-term beneficial impact remains uncertain. Still, interest and activity in this field are 348 proliferating to identify factors underlying variable nutritional responses and develop 349 algorithms to predict individual responses to nutrients, foods, and dietary patterns.

350

351 Our systematic review had some limitations. The scope of our literature review as part of the 352 PDMI was broad and inclusive of diverse study designs, T2D prevention strategies, study 353 populations, and effect modification analyses. Although this resulted in a heterogeneous 354 evidence base and did not provide an opportunity for meta-analysis, we qualitatively 355 synthesized the evidence for precision prevention generally. Our hypothesis originally 356 spanned to include observational studies, which were ultimately excluded due to the 357 uncertainty of their being readily related to clinical interventions. Protocol amendments were 358 registered to reflect these decisions prior to study screening and extraction.

359

In conclusion, our systematic review and synthesis of the T2D prevention literature provide
 low to very low certainty evidence that sociodemographic, clinical, lifestyle, or molecular

- 362 factors are more useful, valid, and consistent in informing T2D precision prevention
- 363 strategies than current interventions. We also uncover several areas of potential for growth
- in the precision medicine field, including prospectively designed interventions and clinical
- 365 trials incorporating the investigation of treatment response heterogeneity.

### 366 AUTHOR CONTRIBUTIONS

DB, RM, SLF, JSP, PWF, DT, JM, VM, and RJFL contributed to the conception and design
of the research questions. All authors contributed to the study screening and data extraction.
DT and JM did the quality assessment; DB, RM, VS, MN, SLF, MGF, JSP, MRL, DT, JM,
VM, and RJFL summarized and interpreted the data. DB, JM, and RJFL drafted the paper;
DT and VM revised it substantively. All authors edited the manuscript and approved the final
version.

373

### 374 CONFLICTS OF INTEREST

RWM and PWF are employees of the Novo Nordisk Foundation, a private philanthropic enterprise foundation. The opinions expressed in this article do not necessarily reflect the perspectives of the Novo Nordisk Foundation. VM has acted as consultant and speaker and received research or educational grants from Novo Nordisk, MSD, Eli Lilly, Novartis, Boehringer Ingelheim, Lifescan J & J, Sanofi-Aventis, Roche Diagnostics, Abbott, and several Indian pharmaceutical companies, including USV, Dr. Reddy's Laboratories, and Sun Pharma. None of the other authors have any conflicts of interest to declare.

382

### 383 FUNDING

384 The ADA/EASD Precision Diabetes Medicine Initiative, within which this work was 385 conducted, has received the following support: The Covidence license was funded by Lund 386 University (Sweden), for which technical support was provided by Maria Björklund and 387 Krister Aronsson (Faculty of Medicine Library, Lund University, Sweden). Administrative 388 support was provided by Lund University (Malmö, Sweden), the University of Chicago (IL, 389 USA), and the American Diabetes Association (Washington D.C., USA). The Novo Nordisk 390 Foundation (Hellerup, Denmark) provided grant support for in-person writing group meetings 391 (PI: L Phillipson, University of Chicago, IL). DB was supported through an Early Career 392 Research grant (ECR/2017/000640) from Science and Engineering Research Board

- 393 (SERB), India. JM was partially supported by funding from the American Diabetes
- 394 Association (7-21-JDFM-005) and the National Institutes of Health (P30 DK40561 and UG1
- 395 HD107691). RJFL received support through NNF18CC0034900; NNF20OC0059313
- 396 (Laureate Award); DNRF161 (Chair).

## 397 **REFERENCES**

- Sun, H. *et al.* IDF Diabetes Atlas: Global, regional and country-level diabetes
   prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* 183, 109119 (2022).
- 401 2. Tuomi, T. *et al.* The many faces of diabetes: a disease with increasing heterogeneity.
  402 *Lancet* 383, 1084–94 (2014).
- 403 3. Knowler, W. C. *et al.* Reduction in the incidence of type 2 diabetes with lifestyle
  404 intervention or metformin. *N Engl J Med* 346, 393–403 (2002).
- 405 4. Tuomilehto, J. *et al.* Prevention of type 2 diabetes mellitus by changes in lifestyle
  406 among subjects with impaired glucose tolerance. *N Engl J Med* 344, 1343–50 (2001).
- 407 5. Pan, X. R. *et al.* Effects of diet and exercise in preventing NIDDM in people with
  408 impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care* 20,
  409 537–44 (1997).
- 410 6. Ramachandran, A. *et al.* The Indian Diabetes Prevention Programme shows that
  411 lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects
  412 with impaired glucose tolerance (IDPP-1). *Diabetologia* 49, 289–97 (2006).
- 413 7. Ling, W. *et al.* Global trend of diabetes mortality attributed to vascular complications,
  414 2000–2016. *Cardiovasc Diabetol* **19**, (2020).
- 8. Chung, W. K. *et al.* Precision Medicine in Diabetes: A Consensus Report from the
  American Diabetes Association (ADA) and the European Association for the Study of
  Diabetes (EASD). *Diabetes Care* 43, 1617–1635 (2020).
- 418 9. Xie, F., Chan, J. C. N. & Ma, R. C. W. Precision medicine in diabetes prevention,
  419 classification and management. *Journal of Diabetes Investigation* vol. 9 998–1015
  420 Preprint at https://doi.org/10.1111/jdi.12830 (2018).
- Mutie, P. M., Giordano, G. N. & Franks, P. W. Lifestyle precision medicine: The next
  generation in type 2 diabetes prevention? *BMC Medicine* vol. 15 Preprint at
  https://doi.org/10.1186/s12916-017-0938-x (2017).
- Nolan, J. J. *et al.* ADA/EASD Precision Medicine in Diabetes Initiative: An
  International Perspective and Future Vision for Precision Medicine in Diabetes. *Diabetes Care* 45, 261–266 (2022).
- 427 12. Covidence systematic review software. Veritas Health Innovation, Melbourne,
  428 Australia. Available at www.covidence.org.
- Barker, T. H. *et al.* The revised JBI critical appraisal tool for the assessment of risk of
  bias for randomized controlled trials. *JBI Evid Synth* 21, 494–506 (2023).
- 431 14. Sherifali, D. et al. Methods. Can J Diabetes 42, S6–S9 (2018).
- 432 15. Gong, Q. *et al.* Efficacy of lifestyle intervention in adults with impaired glucose
  433 tolerance with and without impaired fasting plasma glucose: A post hoc analysis of Da
  434 Qing Diabetes Prevention Outcome Study. *Diabetes Obes Metab* 23, 2385–2394
  435 (2021).
- 436 16. Weber, M. B. *et al.* The Stepwise Approach to Diabetes Prevention: Results From the
  437 D-CLIP Randomized Controlled Trial. *Diabetes Care* **39**, 1760–7 (2016).

- Aekplakorn, W. *et al.* Evaluation of a Community-Based Diabetes Prevention Program
  in Thailand: A Cluster Randomized Controlled Trial. *J Prim Care Community Health* **10**, 2150132719847374 (2019).
- 18. Sakane, N. *et al.* Prevention of type 2 diabetes in a primary healthcare setting: threeyear results of lifestyle intervention in Japanese subjects with impaired glucose
  tolerance. *BMC Public Health* **11**, 40 (2011).
- 444 19. Wagner, R. *et al.* Pathophysiology-based subphenotyping of individuals at elevated 445 risk for type 2 diabetes. *Nat Med* **27**, 49–57 (2021).
- 446 20. Ben-Yacov, O. *et al.* Personalized Postprandial Glucose Response-Targeting Diet
  447 Versus Mediterranean Diet for Glycemic Control in Prediabetes. *Diabetes Care* 44,
  448 1980–1991 (2021).
- 449 21. Berry, S. E. *et al.* Human postprandial responses to food and potential for precision nutrition. *Nat Med* **26**, 964–973 (2020).
- 451 22. Zeevi, D. *et al.* Personalized Nutrition by Prediction of Glycemic Responses. *Cell* 163, 1079–1094 (2015).
- 453 23. Delgado-Lista, J. *et al.* CORonary Diet Intervention with Olive oil and cardiovascular
  454 PREVention study (the CORDIOPREV study): Rationale, methods, and baseline
  455 characteristics: A clinical trial comparing the efficacy of a Mediterranean diet rich in
  456 olive oil versus a low-fat diet on cardiovascular disease in coronary patients. *Am*457 *Heart J* 177, 42–50 (2016).
- 458 24. Jimenez-Lucena, R. *et al.* MiRNAs profile as biomarkers of nutritional therapy for the
  459 prevention of type 2 diabetes mellitus: From the CORDIOPREV study. *Clin Nutr* 40,
  460 1028–1038 (2021).
- 461 25. Estruch, R. *et al.* Primary Prevention of Cardiovascular Disease with a Mediterranean
  462 Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N Engl J Med* **378**, e34 (2018).
- 463 26. Ruiz-Canela, M. *et al.* Plasma branched chain/aromatic amino acids, enriched
  464 Mediterranean diet and risk of type 2 diabetes: case-cohort study within the
  465 PREDIMED Trial. *Diabetologia* 61, 1560–1571 (2018).
- 466 27. Corella, D. *et al.* CLOCK gene variation is associated with incidence of type-2
  467 diabetes and cardiovascular diseases in type-2 diabetic subjects: dietary modulation
  468 in the PREDIMED randomized trial. *Cardiovasc Diabetol* **15**, 4 (2016).
- 469 28. Ibarrola-Jurado, N., Salas-Salvadó, J., Martínez-González, M. A. & Bulló, M. Dietary
  470 phylloquinone intake and risk of type 2 diabetes in elderly subjects at high risk of
  471 cardiovascular disease. *Am J Clin Nutr* **96**, 1113–8 (2012).
- 472 29. Liu, X. *et al.* High plasma glutamate and low glutamine-to-glutamate ratio are
  473 associated with type 2 diabetes: Case-cohort study within the PREDIMED trial. *Nutr*474 *Metab Cardiovasc Dis* 29, 1040–1049 (2019).
- 475 30. Salas-Salvadó, J. *et al.* Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. *Ann Intern Med* **160**, 1–10 (2014).
- 477 31. Salas-Salvadó, J. *et al.* Reduction in the incidence of type 2 diabetes with the
  478 Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized
  479 trial. *Diabetes Care* 34, 14–9 (2011).

- Shahbazi, S. & Vahdat Shariatpanahi, Z. Prevention of type 2 diabetes mellitus by
  changes in diet among subjects with abnormal glucose metabolism: a randomized
  clinical trial. *Int J Diabetes Dev Ctries* 38, 69–74 (2018).
- Tinker, L. F. *et al.* Low-fat dietary pattern and risk of treated diabetes mellitus in
  postmenopausal women: the Women's Health Initiative randomized controlled dietary
  modification trial. *Arch Intern Med* **168**, 1500–11 (2008).
- 486 34. Howard, B. V *et al.* A Low-Fat Dietary Pattern and Diabetes: A Secondary Analysis
  487 From the Women's Health Initiative Dietary Modification Trial. *Diabetes Care* 41, 680–
  488 687 (2018).
- 489 35. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods,
  490 participant characteristics, and compliance. The ATBC Cancer Prevention Study
  491 Group. Ann Epidemiol 4, 1–10 (1994).
- 492 36. Kataja-Tuomola, M. *et al.* Effect of alpha-tocopherol and beta-carotene
  493 supplementation on the incidence of type 2 diabetes. *Diabetologia* 51, 47–53 (2008).
- 494 37. Pittas, A. G. *et al.* Vitamin D Supplementation and Prevention of Type 2 Diabetes. *N* 495 *Engl J Med* 381, 520–530 (2019).
- Song, Y., Cook, N. R., Albert, C. M., Van Denburgh, M. & Manson, J. E. Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. *Diabetes* 58, 1921–8 (2009).
- 39. Song, Y., Cook, N. R., Albert, C. M., Van Denburgh, M. & Manson, J. E. Effects of
  vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high
  risk of cardiovascular disease: a randomized controlled trial. *Am J Clin Nutr* **90**, 429–
  37 (2009).
- 50340.Lee, I.-M. *et al.* Vitamin E in the primary prevention of cardiovascular disease and504cancer: the Women's Health Study: a randomized controlled trial. JAMA 294, 56–65505(2005).
- 506 41. Liu, S. *et al.* Vitamin E and risk of type 2 diabetes in the women's health study 507 randomized controlled trial. *Diabetes* **55**, 2856–62 (2006).
- 508 42. Chae, J. S. *et al.* Supervised exercise program, BMI, and risk of type 2 diabetes in subjects with normal or impaired fasting glucose. *Diabetes Care* **35**, 1680–5 (2012).
- 43. Li, G. *et al.* Cardiovascular mortality, all-cause mortality, and diabetes incidence after
  lifestyle intervention for people with impaired glucose tolerance in the Da Qing
  Diabetes Prevention Study: a 23-year follow-up study. *Lancet Diabetes Endocrinol* 2,
  474–80 (2014).
- 514 44. Li, G. *et al.* Effects of insulin resistance and insulin secretion on the efficacy of
  515 interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and
  516 Diabetes Study. *Diabetes Res Clin Pract* 58, 193–200 (2002).
- 517 45. Costa, B. *et al.* Delaying progression to type 2 diabetes among high-risk Spanish
  518 individuals is feasible in real-life primary healthcare settings using intensive lifestyle
  519 intervention. *Diabetologia* 55, 1319–28 (2012).
- 46. O'Brien, M. J., Whitaker, R. C., Yu, D. & Ackermann, R. T. The comparative efficacy
  of lifestyle intervention and metformin by educational attainment in the Diabetes
  Prevention Program. *Prev Med (Baltim)* **77**, 125–30 (2015).

523 524 525 526	47.	Kriska, A. M. <i>et al.</i> The Impact of Physical Activity on the Prevention of Type 2 Diabetes: Evidence and Lessons Learned From the Diabetes Prevention Program, a Long-Standing Clinical Trial Incorporating Subjective and Objective Activity Measures. <i>Diabetes Care</i> <b>44</b> , 43–49 (2021).
527 528	48.	Allaire, B. T. <i>et al.</i> Diet quality, weight loss, and diabetes incidence in the Diabetes Prevention Program (DPP). <i>BMC Nutr</i> <b>6</b> , 74 (2020).
529 530 531	49.	Billings, L. K. <i>et al.</i> Variation in Maturity-Onset Diabetes of the Young Genes Influence Response to Interventions for Diabetes Prevention. <i>J Clin Endocrinol Metab</i> <b>102</b> , 2678–2689 (2017).
532 533	50.	Crandall, J. P. <i>et al.</i> Alcohol consumption and diabetes risk in the Diabetes Prevention Program. <i>Am J Clin Nutr</i> <b>90</b> , 595–601 (2009).
534 535	51.	Maruthur, N. M. <i>et al.</i> Early response to preventive strategies in the Diabetes Prevention Program. <i>J Gen Intern Med</i> <b>28</b> , 1629–36 (2013).
536 537	52.	Florez, J. C. <i>et al.</i> TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. <i>N Engl J Med</i> <b>355</b> , 241–50 (2006).
538 539 540	53.	Moore, A. F. <i>et al.</i> The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. <i>J Clin Endocrinol Metab</i> <b>94</b> , 449–55 (2009).
541 542	54.	Florez, J. C. <i>et al.</i> Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. <i>Diabetologia</i> <b>51</b> , 451–7 (2008).
543 544 545	55.	Pan, Q. <i>et al.</i> Variation at the melanocortin 4 receptor gene and response to weight- loss interventions in the diabetes prevention program. <i>Obesity (Silver Spring)</i> <b>21</b> , E520-6 (2013).
546 547 548	56.	Diabetes Prevention Program Research Group <i>et al.</i> The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. <i>J Gerontol A Biol Sci Med Sci</i> <b>61</b> , 1075–81 (2006).
549 550 551	57.	Diabetes Prevention Program Research Group <i>et al.</i> 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. <i>Lancet</i> <b>374</b> , 1677–86 (2009).
552 553 554	58.	Raghavan, S. <i>et al.</i> Interaction of diabetes genetic risk and successful lifestyle modification in the Diabetes Prevention Programme. <i>Diabetes Obes Metab</i> <b>23</b> , 1030–1040 (2021).
555 556 557 558	59.	Herman, W. H. <i>et al.</i> Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. <i>Diabetes Care</i> <b>40</b> , 1668–1677 (2017).
559 560 561	60.	Hivert, MF. <i>et al.</i> Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. <i>Diabetes</i> <b>60</b> , 1340–8 (2011).
562 563 564	61.	Jablonski, K. A. <i>et al.</i> Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. <i>Diabetes</i> <b>59</b> , 2672–81 (2010).
565 566	62.	Fujimoto, W. Y. <i>et al.</i> Body size and shape changes and the risk of diabetes in the diabetes prevention program. <i>Diabetes</i> <b>56</b> , 1680–5 (2007).

- 567 63. Sussman, J. B., Kent, D. M., Nelson, J. P. & Hayward, R. A. Improving diabetes
  568 prevention with benefit based tailored treatment: risk based reanalysis of Diabetes
  569 Prevention Program. *BMJ* **350**, h454 (2015).
- 570 64. Diabetes Prevention Program (DPP) Research Group *et al.* Factors affecting the
  571 decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study
  572 (DPPOS). *Diabetes* 64, 989–98 (2015).
- 573 65. Penn, L. *et al.* Prevention of type 2 diabetes in adults with impaired glucose tolerance:
  574 the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. *BMC Public*575 *Health* 9, 342 (2009).
- 576 66. Penn, L. *et al.* Importance of weight loss maintenance and risk prediction in the
  577 prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT.
  578 *PLoS One* **8**, e57143 (2013).
- Mager, U. *et al.* Association of the Leu72Met polymorphism of the ghrelin gene with
  the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish
  Diabetes Prevention Study. *Diabet Med* 23, 685–9 (2006).
- 582 68. Laaksonen, D. E. *et al.* Physical activity, diet, and incident diabetes in relation to an 583 ADRA2B polymorphism. *Med Sci Sports Exerc* **39**, 227–32 (2007).
- Herder, C. *et al.* Systemic immune mediators and lifestyle changes in the prevention
  of type 2 diabetes: results from the Finnish Diabetes Prevention Study. *Diabetes* 55,
  2340–6 (2006).
- 587 70. Kilpeläinen, T. O. *et al.* Interaction of single nucleotide polymorphisms in ADRB2,
  588 ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of
  589 type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome:
  590 The Finnish Diabetes Prevention Study. *Metabolism* 57, 428–36 (2008).
- Tuomilehto, H. *et al.* Sleep duration, lifestyle intervention, and incidence of type 2 diabetes in impaired glucose tolerance: The Finnish Diabetes Prevention Study. *Diabetes Care* 32, 1965–71 (2009).
- Kilpeläinen, T. O. *et al.* Physical activity modifies the effect of SNPs in the SLC2A2
  (GLUT2) and ABCC8 (SUR1) genes on the risk of developing type 2 diabetes. *Physiol Genomics* 31, 264–72 (2007).
- 597 73. Uusitupa, M. I. *et al.* Impact of positive family history and genetic risk variants on the
  598 incidence of diabetes: the Finnish Diabetes Prevention Study. *Diabetes Care* 34, 418–
  599 23 (2011).
- Lindi, V. I. *et al.* Association of the Pro12Ala polymorphism in the PPAR-gamma2
  gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish
  Diabetes Prevention Study. *Diabetes* 51, 2581–6 (2002).
- Laukkanen, O. *et al.* Common polymorphisms in the genes regulating the early insulin
  signalling pathway: effects on weight change and the conversion from impaired
  glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study. *Diabetologia* 47, 871–7 (2004).
- 60776.Lindström, J. et al. Determinants for the effectiveness of lifestyle intervention in the608Finnish Diabetes Prevention Study. Diabetes Care 31, 857–62 (2008).
- Kaaksonen, D. E. *et al.* Physical activity in the prevention of type 2 diabetes: the
  Finnish diabetes prevention study. *Diabetes* 54, 158–65 (2005).

- 511 78. Siitonen, N. *et al.* Association between a deletion/insertion polymorphism in the
  alpha2B-adrenergic receptor gene and insulin secretion and Type 2 diabetes. The
  Finnish Diabetes Prevention Study. *Diabetologia* 47, 1416–24 (2004).
- Kaukkanen, O. *et al.* Polymorphisms in the SLC2A2 (GLUT2) gene are associated
  with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish
  Diabetes Prevention Study. *Diabetes* 54, 2256–60 (2005).
- 617 80. Kilpeläinen, T. O. *et al.* SNPs in PPARG associate with type 2 diabetes and interact 618 with physical activity. *Med Sci Sports Exerc* **40**, 25–33 (2008).
- 81. Todorova, B. *et al.* The G-250A promoter polymorphism of the hepatic lipase gene
  predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus:
  the Finnish Diabetes Prevention Study. *J Clin Endocrinol Metab* 89, 2019–23 (2004).
- 82. Ramachandran, A. *et al.* Effectiveness of mobile phone messaging in prevention of
  type 2 diabetes by lifestyle modification in men in India: a prospective, parallel-group,
  randomised controlled trial. *Lancet Diabetes Endocrinol* 1, 191–8 (2013).
- 83. Nanditha, A. *et al.* Impact of lifestyle intervention in primary prevention of Type 2
  diabetes did not differ by baseline age and BMI among Asian-Indian people with
  impaired glucose tolerance. *Diabet Med* 33, 1700–1704 (2016).
- 84. Ramachandran, A., Arun, N., Shetty, A. S. & Snehalatha, C. Efficacy of primary
  prevention interventions when fasting and postglucose dysglycemia coexist: analysis
  of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2). *Diabetes Care*33, 2164–8 (2010).
- 85. Ramachandran, A. *et al.* Pioglitazone does not enhance the effectiveness of lifestyle
  modification in preventing conversion of impaired glucose tolerance to diabetes in
  Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). *Diabetologia* 52, 1019–26 (2009).
- 63686.Sakane, N. et al. Effect of baseline HbA1c level on the development of diabetes by637lifestyle intervention in primary healthcare settings: insights from subanalysis of the638Japan Diabetes Prevention Program. BMJ Open Diabetes Res Care 2, e000003639(2014).
- 87. Sathish, T. *et al.* Cluster randomised controlled trial of a peer-led lifestyle intervention
  program: study protocol for the Kerala diabetes prevention program. *BMC Public Health* 13, 1035 (2013).
- 88. Thankappan, K. R. *et al.* A peer-support lifestyle intervention for preventing type 2
  diabetes in India: A cluster-randomized controlled trial of the Kerala Diabetes
  Prevention Program. *PLoS Med* 15, e1002575 (2018).
- Kosaka, K., Noda, M. & Kuzuya, T. Prevention of type 2 diabetes by lifestyle
  intervention: a Japanese trial in IGT males. *Diabetes Res Clin Pract* 67, 152–62
  (2005).
- 649 90. Gray, L. J. *et al.* Let's prevent diabetes: study protocol for a cluster randomised
  650 controlled trial of an educational intervention in a multi-ethnic UK population with
  651 screen detected impaired glucose regulation. *Cardiovasc Diabetol* **11**, 56 (2012).
- Bavies, M. J. *et al.* A community based primary prevention programme for type 2
  diabetes integrating identification and lifestyle intervention for prevention: the Let's
  Prevent Diabetes cluster randomised controlled trial. *Prev Med (Baltim)* 84, 48–56
  (2016).

- Bavey Smith, G. *et al.* Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. *Ann Intern Med* **142**, 313–22 (2005).
- Nanditha, A. *et al.* A pragmatic and scalable strategy using mobile technology to
  promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a
  randomised controlled trial. *Diabetologia* 63, 486–496 (2020).
- Saaristo, T. *et al.* Lifestyle intervention for prevention of type 2 diabetes in primary
  health care: one-year follow-up of the Finnish National Diabetes Prevention Program
  (FIN-D2D). *Diabetes Care* 33, 2146–51 (2010).
- Rautio, N. *et al.* Do statins interfere with lifestyle intervention in the prevention of
  diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. *BMJ Open* 2, (2012).
- 867 96. Rintamäki, R. *et al.* Long-term outcomes of lifestyle intervention to prevent type 2
  868 diabetes in people at high risk in primary health care. *Prim Care Diabetes* 15, 444–
  869 450 (2021).
- 870 97. Rautio, N. *et al.* Family history of diabetes and effectiveness of lifestyle counselling on
  871 the cardio-metabolic risk profile in individuals at high risk of Type 2 diabetes: 1-year
  872 follow-up of the FIN-D2D project. *Diabet Med* 29, 207–11 (2012).
- 88. Rautio, N. *et al.* Socioeconomic position and effectiveness of lifestyle intervention in prevention of type 2 diabetes: one-year follow-up of the FIN-D2D project. *Scand J Public Health* **39**, 561–70 (2011).
- 876 99. Raghuram, N. *et al.* Effectiveness of a Yoga-Based Lifestyle Protocol (YLP) in
  877 Preventing Diabetes in a High-Risk Indian Cohort: A Multicenter Cluster-Randomized
  878 Controlled Trial (NMB-Trial). *Front Endocrinol (Lausanne)* 12, 664657 (2021).
- Sampson, M. *et al.* Lifestyle Intervention With or Without Lay Volunteers to Prevent
  Type 2 Diabetes in People With Impaired Fasting Glucose and/or Nondiabetic
  Hyperglycemia: A Randomized Clinical Trial. *JAMA Intern Med* **181**, 168–178 (2021).
- 101. Sanchez, A., Silvestre, C., Campo, N., Grandes, G. & PredDE Group. Effective
  translation of a type-2 diabetes primary prevention programme into routine primary
  care: The PreDE cluster randomised clinical trial. *Diabetes Res Clin Pract* 139, 32–42
  (2018).
- Harati, H. *et al.* Reduction in incidence of type 2 diabetes by lifestyle intervention in a
  middle eastern community. *Am J Prev Med* 38, 628-636.e1 (2010).
- 103. Derakhshan, A. *et al.* Sex specific incidence rates of type 2 diabetes and its risk
  factors over 9 years of follow-up: Tehran Lipid and Glucose Study. *PLoS One* 9, e102563 (2014).
- 104. Norberg, M., Wall, S., Boman, K. & Weinehall, L. The Västerbotten Intervention
  Programme: background, design and implications. *Glob Health Action* 3, (2010).
- Long, G. H. *et al.* Healthy behaviours and 10-year incidence of diabetes: a population cohort study. *Prev Med (Baltim)* **71**, 121–7 (2015).
- Saito, T. *et al.* Lifestyle modification and prevention of type 2 diabetes in overweight
   Japanese with impaired fasting glucose levels: a randomized controlled trial. *Arch Intern Med* **171**, 1352–60 (2011).
- 698

Table 1: Description of study population and study design of the included trials grouped according to the type of intervention

	Stud	Study Population				Main Trial	Included		
Trial/Study Name	Country	Total Enrolled; Inclusion Criteria	Baseline Enrollment Years	Intervention Design	Active Intervention Duration	Intervention(s)	Comparator/ Control Intervention	Info PMIDs	Studies (PMDIs)
DIETARY PATTERN INTE	ERVENTIC	ONS							
CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (CORDIOPREV)	Spain	N=1,002; Prevalent heart disease	2009/12	Randomized, parallel arm	Median 7 years	Mediterranean dietary pattern	AHA low-fat pattern (<30% kcal)	27297848 <sup>23</sup>	32723508 <sup>24</sup>
Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts (PREDIMED)	Spain	N=7,447; High cardiovascular risk	2003/09	Randomized, parallel arm	4.8 years	<ul> <li>(i) Mediterranean</li> <li>pattern + extra-</li> <li>virgin olive oil;</li> <li>(ii) Mediterranean</li> <li>pattern + mixed</li> <li>nuts</li> </ul>	Low-fat pattern	29897866 <sup>25</sup>	29663011 <sup>26</sup> , 26739996 <sup>27</sup> , 23034962 <sup>28</sup> , 31377179 <sup>29</sup> , 24573661 <sup>30</sup> , 20929998 <sup>31</sup>
Shahbazi et al (2018)	Iran	N=336; Prediabetes	2012	Randomized, parallel arm	2 years	<ul> <li>(i) High fat diet from olive oil (45% kcal);</li> <li>(ii) Normal fat diet (30% kcal)</li> </ul>	Standard low- fat diet (<30% kcal)	DOI 10.1007/s13 410-017- 0548-3	DOI 10.1007/s1 3410-017- 0548-3 <sup>32</sup>
Women's Health Initiative Dietary Modification Trial (WHI-DM)	US	N=48,835; Healthy postmenopausal women	1993/98	Randomized, parallel arm	Mean 8.1 years	Low-fat (20% kcal) healthy pattern	Provided with healthy diet materials at baseline	18663162 <sup>33</sup>	29282203 <sup>34</sup>
DIETARY SUPPLEMENT	INTERVE	NTIONS							
Alpha-Tocopherol, Beta- Carotene Lung Cancer Prevention Study (ATBC)	Finland	N=29,133; Men, smokers	1985/88	Randomized, parallel arm	Median 6.1 years	2x2 factorial: (i) alpha-tocopherol (50mg/d), (ii) beta- carotene (20mg/d)	Placebo	8205268 <sup>35</sup>	17994292 <sup>36</sup>
Vitamin D and Type 2 Diabetes Trial (D2d)	US	N=2,423; Prediabetes	2013/17	Randomized, parallel arm	Median 2.5 years	Vitamin D supplementation (4000 IU/day)	Placebo	31173679 <sup>37</sup>	31173679 <sup>37</sup>
Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)	US	N=5,442; Women with cardiovascular disease	1998	Randomized, parallel arm	Median 7.3 years	Folic acid (2.5 mg/d), vitamin B6 (50 mg/d), and vitamin B12 (1 mg/d) combined supplementation	Placebo	19491213 <sup>38</sup>	19491213 <sup>38</sup>

Women's Antioxidant Cardiovascular Study (WACS)	US	N=8,171; Women with cardiovascular disease	1995/96	Randomized, parallel arm	Median 9.2 years	2x2x2 factorial: (i) vitamin C (500 mg/d), (ii) vitamin E (600 IU/d), (iii) beta- carotene (50 mg/eod) supplementation	Placebo	19491386 <sup>39</sup>	19491386 <sup>39</sup>
Women's Health Study (WHS)	US	N=39,876; Healthy women	1992/95	Randomized, parallel arm	10.1 years	2x2 Factorial, every other day: Aspirin (100 mg); (ii) Vitamin E supplementation (600 IU)	Placebo	15998891 <sup>40</sup>	17003353 <sup>41</sup>
LIFESTYLE PROGRAMS	6								
Chae et al (2012)	South Korea	N=7,233; General population	2007/11	Non- randomized, parallel arm	6 months	Physical activity program	Usual care	22688549 <sup>42</sup>	22688549 <sup>42</sup>
Da Qing IGT and Diabetes Study	China	N=577; Prediabetes	1986	Cluster- randomized trial	6 years	(i) Diet: Low-calorie, low-fat (25-30% kcal) healthy pattern; (ii) Increase exercise; (iii) Diet + Exercise	Provided with diabetes education materials at baseline	9096977 <sup>5</sup>	24731674 <sup>43</sup> , 34212465 <sup>15</sup> , 12413779 <sup>44</sup>
Diabetes Community Lifestyle Improvement Program (D-CLIP)	India	N=578; Prediabetes	2009/12	Randomized, parallel arm	3 years	Lifestyle diabetes prevention program + Metformin	Lifestyle diabetes prevention program at baseline	27504014 <sup>16</sup>	27504014 <sup>16</sup>
Diabetes in Europe— Prevention using Lifestyle, Physical Activity and Nutritional - Catalonia (DE-PLAN- CAT)	Spain	N=544; Prediabetes	2006	Non- randomized, parallel arm	4 years	Lifestyle weight loss and diabetes prevention program	Provided with diabetes education materials at baseline	22322921 <sup>45</sup>	22322921 <sup>45</sup>
Diabetes Prevention Program (DPP)	US	N=3,234; Prediabetes	1996/99	Randomized, parallel arm	Mean 2.8 years	<ul><li>(i) Lifestyle weight</li><li>loss and diabetes</li><li>prevention program;</li><li>(ii) Metformin</li></ul>	Usual care + placebo	11832527 <sup>3</sup>	$\begin{array}{ c c c c c c c c c c c c c c c c c c c$

									19017751 <sup>53</sup> 18060660 <sup>54</sup> 11832527 <sup>3</sup> ; 23512951 <sup>55</sup> 17077202 <sup>56</sup> 19878986 <sup>57</sup> 33394545 <sup>58</sup> 29021207 <sup>59</sup> 21378175 <sup>60</sup> 20682687 <sup>61</sup> 17363740 <sup>62</sup> 25697494 <sup>63</sup> 25277389 <sup>64</sup>
EDIPS-Newcastle	UK	N=102; Prediabetes		Randomized, parallel arm	5 years	Lifestyle diabetes prevention program	Usual care	19758428 <sup>65</sup>	23451166 <sup>66</sup>
Finnish Diabetes Prevention Study (DPS)	Finland	N=522; Prediabetes	1993/98	Randomized, parallel arm	Mean 3.2 years	Lifestyle and weight loss diabetes prevention program	Provided with diabetes education materials at baseline	113339904	$\begin{array}{r} 16759313^{67}\\ 17277585^{68}\\ 16873699^{69}\\ 18249219^{70}\\ 19651919^{71}\\ 17636114^{72}\\ 1133390^{4};\\ 20980412^{33}\\ 12145174^{74}\\ 15127203^{75}\\ 18252900^{76}\\ 15616024^{77}\\ 15309292^{78}\\ 15983230^{79}\\ 18091023^{80}\\ 15126514^{81}\end{array}$
Indian Diabetes Prevention Program 2013 (IDPP-2013)	India	N=537; Men with prediabetes	2009	Randomized, parallel arm	24 months	SMS-delivered lifestyle diabetes prevention education	Provided with diabetes education materials at baseline	24622367 <sup>82</sup>	26773871 <sup>83</sup> 16391903 <sup>6</sup>
Indian Diabetes Prevention Programme (IDPP-1)	India	N=531; Prediabetes	2001/02	Randomized, parallel arm	3 years	(i) Lifestyle diabetes prevention program; (ii) Metformin; (iii) Lifestyle + Metformin	Usual care	16391903 <sup>6</sup>	16391903 <sup>6</sup> , 20519663 <sup>84</sup> 26773871 <sup>83</sup>
Indian Diabetes Prevention Programme	India	N=407; Prediabetes	2003/05	Randomized, parallel arm	3 years	Lifestyle diabetes prevention program	Lifestyle diabetes	19277602 <sup>85</sup>	20519663 <sup>84</sup>

(IDPP-2)						+ Pioglitozone	prevention program + Placebo		
Japan Diabetes Prevention Program (Japan DPP)	Japan	N=304; Prediabetes	1999/02	Randomized, parallel arm	3 years	Lifestyle weight loss and diabetes prevention program	Provided with diabetes education materials at baseline	25452854 <sup>86</sup>	25452854 <sup>86</sup> ; 21235825 <sup>18</sup>
Kerala Diabetes Prevention Program (K- DPP)	India	N=1,007; Prediabetes, rural	2013	Cluster- randomized trial	12 months	Peer-led lifestyle diabetes prevention program	Provided with diabetes education materials at baseline	24180316 <sup>87</sup>	29874236 <sup>88</sup>
Kosaka et al (2004)	Japan	N=458; Men with prediabetes	1990/92	Randomized, parallel arm	4 years	Lifestyle weight loss and diabetes prevention program	Lifestyle weight loss and diabetes prevention information only	15649575**	15649575**
Let's Prevent Diabetes	UK	N=880; Prediabetes	2009/11	Cluster- randomized trial	36 months	Lifestyle diabetes prevention program	Provided with diabetes education materials at baseline	22607160 <sup>90</sup>	26740346 <sup>91</sup>
Multiple Risk Factor Intervention Trial (MRFIT)	US	N=12,866; Men with high cardiovascular risk	1973/76	Randomized, parallel arm	6 years	Lifestyle modifications for heart disease prevention	Usual care	15738450 <sup>92</sup>	15738450 <sup>92</sup>
Nanditha, et al (2020)	India, UK	N=2,062; Prediabetes	2012/17	Randomized, parallel arm	24 months	SMS-delivered lifestyle diabetes prevention education	Provided with diabetes education materials at baseline	31919539 <sup>93</sup>	31919539 <sup>93</sup>
National Program for the Prevention of Type 2 Diabetes (FIN-D2D)	Finland	N=2,798; Prediabetes	2004/07	Population- wide intervention	Mean 14 months	Lifestyle weight loss and diabetes prevention program		20664020 <sup>94</sup>	22983785 <sup>95</sup> ; 33771515 <sup>96</sup> ; 21781153 <sup>97</sup> ; 20664020 <sup>94</sup> ; 21622677 <sup>98</sup>
Niyantrita Madhmeha Bharata Abhiyaan (NMB- Trial)	India	N=4,450; Prediabetes	2017	Cluster- randomized trial	3 months	Yoga-based lifestyle diabetes prevention program	Presentation on lifestyle for diabetes prevention at baseline	34177805 <sup>99</sup>	34177805 <sup>99</sup>

Norfolk Diabetes Prevention Study (NDPS)	UK	N=1,028; Prediabetes	2011/18	Randomized, parallel arm	12-46 months	(i) Lifestyle diabetes prevention program; (ii) Lifestyle diabetes prevention program with peer support	Provided with diabetes education materials at baseline	33136119 <sup>100</sup>	33136119 <sup>10</sup>
Prevention of Diabetes in Euskadi (PreDE)	Spain	N=1,088; Prediabetes	2011/13	Cluster- randomized trial	24 months	Lifestyle weight loss and diabetes prevention program	Usual care	29476888 <sup>101</sup>	29476888 <sup>10</sup>
Tehran Lipid and Glucose Study (TLGS)	Iran	N=10,368; General population	1999/01	Non- randomized, cluster	Mean 3.6 years	Lifestyle program for chronic disease prevention	Usual care	20494239 <sup>102</sup>	25029368 <sup>10</sup> <sup>3</sup> ; 20494239 <sup>10</sup>
Thai Diabetes Prevention Program (Thai DPP)	Thailand	N=1,903; Prediabetes	2013	Cluster- randomized trial	24 months	Lifestyle diabetes prevention program	Provided with diabetes education materials at baseline	31079517 <sup>17</sup>	31079517 <sup>17</sup>
Västerbotten Intervention Programme (VIP)	Sweden	N=113, 203; General population	1987- present	Population- wide intervention	Ongoing	Lifestyle CVD and diabetes prevention program		20339479 <sup>104</sup>	25532678 <sup>10</sup>
Zensharen Study for Prevention of Lifestyle Diseases	Japan	N=641; Prediabetes	2004/06	Randomized, parallel arm	36 months	Lifestyle weight loss program + Frequent engagement	Lifestyle weight loss program + Minimal engagement	21824948 <sup>106</sup>	21824948 <sup>10</sup> 6

**Table 2:** Efficacy of T2D preventive interventions according to sociodemographic effect modifiers

	T2D preventive strategies													
	Intens	ive Lifestyle interv	vention	[	Dietary intervention	า	Die	etary Supplement	s					
Modifier	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*					
Age	12	Yes: 7 studies No: 5 studies	Grade D	3	No: 3 studies	Grade D	4	Yes: 1 study No: 3 studies	Grade D					
Sex	16	Yes: 1 study No: 15 studies	Grade D	2	No: 2 studies	Grade D	1	Yes: 1 study	Grade D					
Race/ethnicity	3	No: 3 studies	Grade D	1	No: 1 study	Grade D	1	No: 1 study	Grade D					
Socioeconomic status/ Education	5	Yes: 1 study No: 4 studies	Grade D	-	-	-	-	-	-					
Location	2	No: 2 studies	Grade D	-	-	-	1	No: 1 study	-					

**Table legend:** Overview of the included studies investigating whether sociodemographic factors modify the response to T2D preventive intervention strategies. <sup>#</sup> Yes/ No corresponds to significant/ nonsignificant effect modification, as reported in the study. \*Certainty of evidence denotes consistency, Grading based on Diabetes Canada scale A to D.

**Table 3:** Efficacy of T2D preventive interventions according to clinical effect modifiers

				T2D	preventive strateg	gies			
	Intensi	ive Lifestyle interve	ention	[	Dietary interventior	า	Die	etary Supplement	s
Modifier	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*
BMI	14	Yes: 5 studies No: 9 studies	Grade D	3	No: 3 studies	Grade D	4	Yes: 1 study No: 3 studies	Grade D
Prediabetes	18	Yes: 8 studies No: 10 studies	Grade D	1	No: 1 study	Grade D	1	No: 1 study	Grade D
Family history	3	Yes: 1 study No: 2 studies	Grade D	-	-		3	Yes: 2 studies No: 1 study	Grade D
Dyslipidemia/ medications	1	No: 1 study	Grade D	2	Yes: 2 studies	Grade D	2	Yes: 1 study No: 1 study	Grade D
Hypertension	-	-	-	2	Yes: 1 study No: 1 study	Grade D	2	No: 2 studies	Grade D
Metabolic syndrome	-	-	-	1	Yes: 1 study	Grade D	1	No: 1 study	Grade D
Menopausal status, HRT use	-	-	-	-	-	-	3	No: 3 studies	Grade D

**Table legend:** Overview of the included studies investigating whether clinical factors modify the response to T2D preventive intervention strategies. <sup>#</sup> Yes/ No corresponds to significant/ nonsignificant effect modification, as reported in the study. \*Certainty of evidence denotes consistency, Grading based on Diabetes Canada scale A to D.

Table 4: Efficacy	of T2D preventive	e interventions accordin	g to behaviora	l effect modifiers
-------------------	-------------------	--------------------------	----------------	--------------------

				T2D	preventive strateg	jies			
	Intensi	ive Lifestyle interv	ention		Dietary intervention	ı	Die	etary Supplement	s
Modifier	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*
Smoking	2	Yes: 2 studies	Grade D	1	No: 1 study	Grade D	3	No: 3 studies	Grade D
Physical activity	3	Yes: 2 studies No: 1 study	Grade D	1	No: 1 study	Grade D	3	No: 3 studies	Grade D
Alcohol intake	1	Yes: 1 study	Grade D	-	-	-	3	No: 3 studies	Grade D
Diet and supplements	-	-	-	2	No: 2 studies	Grade D	6	No: 6 studies	Grade D

**Table legend:** Overview of the included studies investigating whether behavioral factors at baseline modify the response to T2D preventive intervention strategies. <sup>#</sup> Yes/ No corresponds to significant/ nonsignificant effect modification, as reported in the study. \*Certainty of evidence denotes consistency, Grading based on Diabetes Canada scale A to D.

**Table 5:** Efficacy of T2D preventive interventions according to molecular effect modifiers

	T2D preventive strategies											
	Intensi	ve Lifestyle interve	ention	D	Dietary intervention							
Modifier	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*	Number of Studies	Effect modification <sup>#</sup>	Certainty of evidence*						
T2D single SNPs	16	Yes: 10 studies No: 6 studies	Grade D	1	Yes: 1 study	Grade D						
Diabetes polygenic score	5	Yes: 1 study No: 4 studies	Grade D	-	-	-						
Metabolites/ miRNA	-	-	-	3	Yes: 3 studies	Grade D						

**Table legend:** Overview of the included studies investigating whether genetic and molecular factors at baseline modify the response to T2D preventive intervention strategies. <sup>#</sup> Yes/ No corresponds to significant/ nonsignificant effect modification, as reported in the study. \*Certainty of evidence denotes consistency, Grading based on Diabetes Canada scale A to D.





**Figure Legend:** Stepwise screening stages adapted for selecting the studies of interest using Covidence software. Screening at all stages was done by two independent reviewers and conflicts resolved by a third reviewer.

**Figure 2:** Potential effect modifiers of lifestyle, diet, and diet supplements intervention on the incidence of T2D



Figure Legend: General overview of potential effect modifiers of lifestyle (Panel A), dietary (Panel B), and supplement (Panel C) interventions on the incidence of type 2 diabetes. The Y axes indicate potential effect modifiers, and the X axes illustrate the total number of trial participants included in the studies investigating each modifier. The proportion of grey or white in each bar indicates the number of trial participants included in the studies where there was (grey) or was not (white) an effect by the effect modifier. Caution is warranted because whether an effect modifier did (or did not) have an effect is based on statistical significance from the publication's summary statistics, and it is improbable that the effect modifier strictly did (or did not) have an effect on every participant included in that publication. The number of trials and trial participants are plotted because some trials (eg DPP) had multiple studies published using the same participants such that the participant number would be heavily skewed. There was no instance where the same trial had multiple published studies evaluating the same effect modifier showing different results (e.g., there was no difference between sexes on the PREDIMED trial's effect on T2D incidence in their primary versus subgroup studies/publications). The number at the end of each bar represents the number of trials for each potential effect modifier. \*indicates an exception for genetics because the effect modifiers (SNPs or GRS) were all uniquely distinct but are presented together under the categories of "SNP" or "GRS" here.